SCHEDULE 14A INFORMATION
Proxy Statement Pursuant To Section 14(a) Of
The Securities Exchange Act Of 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement
[_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY
RULE 14A-6(E)(2))
[_] Definitive Proxy Statement
[X] Definitive Additional Materials
[_] Soliciting Material Pursuant to Section 240.14a-12
ICN Pharmaceuticals, Inc.
--------------------------------------------------------
(Name of Registrant as Specified in its Charter)
N/A
--------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
-------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
-------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
-------------------------------------------------------------------
(5) Total fee paid:
-------------------------------------------------------------------
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
-------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
-------------------------------------------------------------------
(3) Filing Party:
-------------------------------------------------------------------
(4) Date Filed:
-------------------------------------------------------------------
Following is the text of an advertisement by ICN on May 29, 2001:
This is ICN
Creating Value Through Performance
[Graphic omitted of man at finish line]
Financial Growth
[1,3]REVENUES
[BAR GRAPH OMITTED - 1995 $273
1996 $347
1997 $627
1998 $696
1999 $747
2000 $800]
Compounded
Growth 24%
6 years of Record
Revenues
[3]DIVIDENDS
[BAR GRAPH OMITTED - 1995 $0.29
1996 $0.28
1997 $0.24
1998 $0.21
1999 $0.20
2000 $0.19]
Compounded
Growth 9%
[1,3]OPERATING INCOME
[BAR GRAPH OMITTED - 1995 $47
1996 $43
1997 $65
1998 $121
1999 $199
2000 $184]
Compounded
Growth 31%
1 Excludes Yugoslavia.
2 Excludes Eastern European charges, including losses incurred in
Yugoslavia in the second quarter of 1998, losses incurred in the third
quarter of 1998, relaxed to the Russian economic crisis, and the
write-off of ICN Yugoslavia.
3 Charts not to scale.
* Cumulative returns based on the stock price as of close of business
12/29/00 excluding dividend reinvestment source Bloomber.
Performance...Reaching
New Heights
-----------
Record Performance
Record 2000 revenues of $800 million...another record year
Growing Royalty Stream
2000 Ribavirin royalties grew 42% to $155 million
Increased R&D Investment
Focused on new drug discoveries
Strong Stock Performance
One Year Return* Five Year Return* Ten Year Return*
21% 59% 967%
ICN stockholders are strongly advised to read the proxy statement relating
to ICN's 2001 annual meting of stockhholders, as it contains important
information Stockholders can obtain this proxy statement, any amendments to
the proxy statement and other documents filed by ICN with the Securities
and Exchange Commission without charge at the Internet website maintained
by the Securities and Exchange Commission at www.sec.gov. In addition, ICN
has mailed the proxy statement to each stockholder of record on the record
date established for the stockholders meeting. ICN will also make
additional copies of the proxy statement and any amendments to the proxy
statement available without charge to ICN's stockholders. Please direct
your request for the proxy statement to Investor Relations, ICN
Pharmaceuticals, Inc., 3300 Hyland Avenue, Costa Mesa, California 92626,
telephone (714) 545-0100, extension 3104 or to Georgeson Shareholder at
(800)-223-2064.
Vote the White ICN Proxy card today.
[LOGO - ICN] To vote your proxy via fax (toll-free)
1-877-260-0406. For shares held in bank or
broker name call Georgeson Shareholder
ICN Pharmaceuticals, Inc. 1-800-223-2064 for instructions.